Serum antibody coupled with the construction of gentamicin sulfate for the Escherichia coli targeted drug.
Conjugates of the Escherichia coli serum antibody (Ab) with the gentamicin sulfate (GM sulfate) have been evaluated for the assessment of their ability to eradicate E. coli in vitro. The combination of every component in the targeted drug is the amino of serum antibody and gentamicin sulfate combined with the hydroxyl of PEG6000 by hydrogen bond, which forms stable complexes. The half-life of this complex is 4.83 h, and it is non-toxic side effects and low immunogenic. After the combination of antibody and gentamicin sulfate, the targeting of antibody is quite good. In vitro anti-bacterial activity of gentamicin sulfate increased 1000 times, and the clinical curative effect enhanced 100 times, this means higher efficacy and safety.